Proteome Sciences (LSE:PRM) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


What is Proteome Sciences Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Proteome Sciences's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

LSE:PRM vs TMO, DHR, IDXX: Margin of Safety % (DCF FCF Based) Comparison

For the Diagnostics & Research subindustry, Proteome Sciences's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Proteome Sciences Margin of Safety % (DCF FCF Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Proteome Sciences's Margin of Safety % (DCF FCF Based) falls into.


Proteome Sciences Business Description

Other Exchanges PRMl:UKPI2:Germany
Address Downside Bridge Road, Coveham House, Cobham, Surrey, GBR, KT11 3EP
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.